文献速递血栓与止血造血干细胞移植与细胞治疗

HIGH-2-LOW风险模型预测异基因移植患者血小板植入后静脉血栓栓塞

HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment.
PubMed 文献 · Blood Adv · 2021-01-01

该研究基于2006至2015年接受首次异基因造血干细胞移植的1703例患者,建立并内部验证了预测血小板植入后静脉血栓栓塞的风险评估模型HIGH-2-LOW。模型包含7个移植后30天可获得的预测因子,约16%患者被归为高危,高危组100天VTE发生率为10.3%,低危组为1.5%。

要点

  • HIGH-2-LOW模型包含7个移植后30天预测因子,用于识别血小板植入后VTE高危患者。
  • 高危组100天VTE发生率为10.3%,低危组为1.5%,高危组VTE比值比为5.87。
  • 该模型可能有助于筛选可从血小板植入后早期血栓预防中获益的异基因移植患者。

核心结论

  • HIGH-2-LOW模型是新工具,可能有助于识别血小板植入后可从早期血栓预防中获益的高危异基因移植患者。

研究设计与样本

  • 研究纳入2006至2015年接受首次异基因造血干细胞移植的患者1703例,用于推导并内部验证风险模型。
  • 以移植后第30天为索引日期,采用逐步逻辑回归建模,并通过1000次自助重抽样进行内部验证。

主要发现

  • 约16%患者被归为高危,高危组100天VTE发生率为10.3%,低危组为1.5%。
  • 100天VTE比值比在高危组为5.87(95%CI 2.98-11.57),中危组为2.71(95%CI 1.38-5.35),均以低危组为参照。

关键数值与推荐

  • HIGH-2-LOW模型包含7个移植后30天预测因子:导管相关深静脉血栓史、第30天住院状态、3-4级移植物抗宿主病、肺栓塞或下肢深静脉血栓史、淋巴瘤诊断、体重指数≥35 kg/m2的肥胖、白细胞计数≥11×10^9/L。

临床怎么用

  • 临床可在移植后30天评估上述7个因子,识别VTE高危患者,考虑血小板植入后早期血栓预防。

局限性

  • 模型仅进行内部验证,尚需外部验证确认其普适性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism (VTE) after allogeneic hematopoietic cell transplantation (HCT) is a significant treatment-associated complication, although optimal timing of thromboprophylaxis remains uncertain when weighing concurrent risks of bleeding. We aimed to derive and internally validate a risk assessment model (RAM) using patients who underwent first allogeneic HCT from 2006 through 2015 (n = 1703). Index date was defined as the 30th day after transplant, at which point we estimated >75% of patients would have achieved platelet engraftment >50 × 109/L. Stepwise logistic regression modeling was used for model development, and internal validation was achieved by fitting a logistic regression model with 1000 bootstrapped resamples to estimate the optimism-corrected c-statistic. The final RAM, "HIGH-2-LOW," included 7 predictors obtained at 30 days after transplant: History of catheter-related deep venous thrombosis (DVT), Inpatient at day 30, Graft-versus-host disease grade 3 to 4, History of pulmonary embolism or lower-extremity DVT, Lymphoma diagnosis, Obesity with body mass index ≥35 kg/m2, and White blood cell count ≥11 × 109/L. Approximately 16% of patients were stratified as high risk, with incident VTE rate of 10.3% at 100 days compared with 1.5% for those at low risk. VTE odds ratios at 100 days were 5.87 (95% confidence interval [CI], 2.98-11.57) and 2.71 (95% CI, 1.38-5.35) in the high- and intermediate-risk vs low-risk groups, respectively. HIGH-2-LOW model serves as a novel and potentially clinically meaningful tool to identify high-risk allogeneic HCT patients who may benefit from early thromboprophylaxis after platelet engraftment.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Martens KL, da Costa WL, Amos CI, et al. HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment. Blood Adv. 2021. PMID: 33570631. doi:10.1182/bloodadvances.2020003353

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。